Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States

被引:8
作者
Asche, Carl V. [1 ,2 ,3 ]
Zografos, Panagiotis [4 ]
Norlin, Jenny M. [5 ]
Urbanek, Bill [4 ]
Mamay, Carl [4 ,6 ]
Makin, Charles
Erntoft, Sandra [5 ]
Chen, Chi-Chang [6 ]
Hines, Dionne M. [6 ]
Siegel, Daniel Mark [7 ,8 ]
机构
[1] Univ Illinois, Coll Med, Ctr Outcomes Res, One Illini Dr, Peoria, IL 61656 USA
[2] Univ Illinois, Coll Med, Dept Med, Peoria, IL 61656 USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[4] LEO Pharma Inc, Parsippany, NJ USA
[5] LEO Pharma A S, Ballerup, Denmark
[6] IMS Hlth, RWE HEOR Plymouth Meeting, Philadelphia, PA USA
[7] Suny Downstate, Dept Dermatol, Brooklyn, NY USA
[8] Long Isl Skin Canc Dermatol Surg, Smithtown, NY USA
关键词
actinic keratosis; health care resource utilization; treatment patterns; PHOTODYNAMIC THERAPY; FIELD CANCERIZATION; ECONOMIC-EVALUATION; SOLAR KERATOSES; CELL CARCINOMA; POPULATION; RISK; EPIDEMIOLOGY; NETHERLANDS; PREVALENCE;
D O I
10.1016/j.jval.2015.11.014
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To compare health care resource utilization and treatment patterns between patients with actinic keratosis (AK) treated with ingenol mebutate gel (IngMeb) and those treated with other field directed AK therapies. Methods: A retrospective, propensity-score matched, cohort study compared refill/repeat and adding-on/switching patterns and outpatient visits and prescriptions (health care resource utilization) over 6 months in patients receiving IngMeb versus those receiving imiquimod, 5-fluorouracil, diclofenac sodium, and methyl aminolevulinate or aminolevulinic acid photodynamic therapy (MAL/ALA-PDT). Results: The final sample analyzed included four matched treatment cohort pairs (IngMeb and comparator; n = 790-971 per treatment arm). Refill rates were similar except for imiquimod (15% vs. 9% for imiquimod and IngMeb, respectively; P < 0.05). MAL/ALA-PDT treatment repetition rates were higher than IngMeb refill rates (20% vs. 10%; P < 0.05). Topical agent add-on/switch rates were comparable. PDT had higher switch rates than did IngMeb (5% vs. 2%; P < 0.05). The IngMeb cohort had a significantly lower proportion of patients with at least one AK-related outpatient visit during the 6-month follow-up than did any other cohort: versus imiquimod (50% vs. 66%; P < 0.0001), versus 5-fluorouracil (50% vs. 69%; P < 0.0001), versus diclofenac sodium (51% vs. 56%; P = 0.034), and versus MAL/ALA-PDT (50% vs. 100%; P < 0.0001). There were significantly fewer AK-related prescriptions among patients receiving IngMeb than among patients in other cohorts. Conclusions: Results based on the first 6 months after treatment initiation suggested that most field-directed AK therapies had clinically comparable treatment patterns except imiquimod, which was associated with higher refill rates, and PDT, which was associated with significantly more frequent treatment sessions and higher switching rates. IngMeb was also associated with significantly fewer outpatient visits than were other field-directed therapies.
引用
收藏
页码:239 / 248
页数:10
相关论文
共 40 条
  • [1] Berman B, 2014, J DRUGS DERMATOL, V13, P154
  • [2] Pathobiology of actinic keratosis: Ultraviolet-dependent keratinocyte proliferation
    Berman, Brian
    Cockerell, Clay J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (01) : S10 - S19
  • [3] Pharmacotherapy of actinic keratosis: an update
    Berman, Brian
    Amini, Sadegh
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (13) : 1847 - 1871
  • [4] Berman B, 2012, CUTIS, V89, P294
  • [5] Braakhuis BJM, 2003, CANCER RES, V63, P1727
  • [6] Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma
    Caekelbergh, K.
    Annemans, L.
    Lambert, J.
    Roelandts, R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) : 784 - 790
  • [7] Actinic Keratosis: Review of the Literature and New Patents
    Cantisani, Carmen
    De Gado, Federico
    Ulrich, Martina
    Bottoni, Ugo
    Iacobellis, Francis
    Richetta, Antonio G.
    Calvieri, Stefano
    [J]. RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2013, 7 (02) : 168 - 175
  • [8] D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
  • [9] 2-B
  • [10] Dinehart SM., 2000, DERMATOL SURG, V26, P728